Revelation Biosciences Inc (NASDAQ: REVB) announced that a recently completed exploratory biomarker analysis confirmed clinical development plans for REVTx-300 in treating chronic kidney disease (CKD) ...
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback